Skip to content
    Font Size

    New Drug May Help Some Prostate Cancer Patients

    Study found Xofigo also improved quality of life for those whose cancer had spread to the bones

    WebMD News from HealthDay

    By Amy Norton

    HealthDay Reporter

    WEDNESDAY, July 17 (HealthDay News) -- A newly approved drug that emits radioactive particles can help extend the lives of certain men with advanced prostate cancer, a clinical trial finds.

    Experts said the results, published in the July 18 issue of the New England Journal of Medicine, offer some good news for men whose cancer has migrated to the bones -- a common and painful feature of advanced prostate cancer.

    The drug, which is marketed as Xofigo, is intended for men with cancer that has spread to the bones despite standard treatment to cut the body's levels of testosterone -- the "male" hormone that fuels prostate cancer growth.

    Known generically as radium-223, the drug emits radioactive particles that zero in on cancerous tissue in the bones. In the new study, researchers found that men given Xofigo had a lower death rate and better quality of life than those on standard treatment only.

    Xofigo is already on the market in the United States, after getting an expedited approval from the U.S. Food and Drug Administration in May. That was based on findings from the current trial, which was designed and funded by drug makers Bayer and Algeta.

    The study was supposed to last three years, but it was stopped early when interim results showed that men on the drug had a clear survival advantage.

    Those patients typically survived for 15 months, versus 11 months among men who received an inactive placebo in addition to standard treatment.

    That "might not sound like very much," said lead researcher Dr. Christopher Parker, of Royal Marsden Hospital in the United Kingdom. "On the other hand, this represents a 30 percent improvement in survival in a group of patients who had a very poor prognosis."

    More important, the extra time tended to be better-quality time, said a cancer specialist who was not involved in the research.

    If a cancer therapy gives people more months of life, but those months are filled with debilitating treatment side effects, then the longer survival may not be worth it, said Dr. Neha Vapiwala, a radiation oncologist at the University of Pennsylvania in Philadelphia.

    1 | 2 | 3

    Today on WebMD

    man with doctor
    Symptoms, risks, treatments
    man coughing
    Men shouldn’t ignore
    prostate cancer cells
    What does this diagnosis mean?
    doctor and male patient
    Is it worth it?
    cancer fighting foods
    15 Cancer Symptoms Men Ignore
    Prostate Enlarged
    Picture Of The Prostate
    Prostate Cancer Quiz
    screening tests for men
    Prostate Cancer Symptoms
    Vitamin D